ICER’s report reviews evidence on the comparative clinical effectiveness and value of poly (ADP-ribose) polymerase (PARP) inhibitors for treatment of ovarian cancer. For questions or additional information, please contact info@icer.org. Interventions of Interest: Rucaparib (Rubraca®, Clovis Oncology) Niraparib (Zejula®, Tesaro, Inc.) Olaparib (Lynparza®, AstraZeneca) View the Key Stakeholders List. Final Documents Below you will find […]
Computed tomography colonography (CT colonography or CTC) is a minimally invasiveradiological technique used to provide images of the colon and rectum. CTC has been suggested as an alternative or as complementary to conventional colonoscopy and other population-based screening methods for colorectal cancer. Given that only 40%-60% of eligible patients undergo recommended screening for colorectal cancer, […]
Prostate cancer is the second leading cause of cancer deaths and the seventh overall cause of death in men in the United States (Centers for Disease Control and Prevention, 2008). Given that most new cases are diagnosed at an early, localized stage, significant attention has been focused on understanding the risks and benefits of alternative […]
This report examines the comparative effectiveness and value of screening options for women with dense breast tissue, including hand-held and automated breast ultrasound, digital breast tomosynthesis (DBT), and magnetic resonance imaging (MRI). For questions, contact info@icer.org. Final Documents Below you will find the final documents from the assessment review process:
Following a negative mammogram, many women with dense breast tissue face a decision: whether to receive additional screening, and if so, what modality to use. Many mammography facilities are now informing women with dense breasts about the potential for “masking” and the increased risk of breast cancer associated with dense breast tissue. Masking occurs when […]
Following a negative mammogram, many women with dense breast tissue face a decision: whether to receive additional screening, and if so, what modality to use. Many mammography facilities are now informing women with dense breasts about the potential for “masking” and the increased risk of breast cancer associated with dense breast tissue. Masking occurs when […]
ICER developed a report on chimeric antigen receptor t-cell (CAR-T) therapies for treatment of B-cell malignancies. Interventions of Interest: tisagenlecleucel (KymriahTM , Novartis) axicabtagene ciloleucel (YescartaTM, Kite Pharma) Both agents were approved in 2017. Tisagenlecleucel is approved for treatment of relapsed or refractory B-cell acute lymphoblastic leukemia in pediatric and young adult patients. Axicabtagene ciloleucel […]
Multiple myeloma is a cancer of the blood in which the bone marrow produces a high number of cancerous plasma cells. The excessive growth of plasma cells can cause bone damage, anemia, hypercalcemia (high calcium levels in the blood), neutropenia (low counts of a certain type of white blood cell), and kidney failure. There is […]
Lung cancer is the number one cause of cancer death in the United States, expected to cause 158,000 deaths in 2016, and accounting for 26.5% of all cancer deaths. It is the second most common cancer in both men (after prostate cancer) and women (after breast cancer), with 118,000 and 106,000 new cases expected in […]
Prostate cancer is the most common nondermatologic cancer in men. In 2006, approximately230,000 new patients in the United States were diagnosed with prostate cancer and 27,000 men died of the disease. The major treatment options for localized prostate cancer include external beam radiation therapy, brachytherapy, surgery, and watchful waiting. Data to compare the long-term survival […]
Recent Comments